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Optimal Treatment Regimes
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Abstract: Variable selection for optimal treatment regime in a clinical
trial or an observational study is getting more attention. Most existing
variable selection techniques focused on selecting variables that are impor-
tant for prediction, therefore some variables that are poor in prediction but
are critical for decision-making may be ignored. A qualitative interaction
of a variable with treatment arises when treatment effect changes direction
as the value of this variable varies. The qualitative interaction indicates the
importance of this variable for decision-making. Gunter, Zhu and Murphy
(2011) proposed S-score which characterizes the magnitude of qualitative
interaction of each variable with treatment individually. In this article, we
developed a sequential advantage selection method based on the modified
S-score. Our method selects qualitatively interacted variables sequentially,
and hence excludes marginally important but jointly unimportant variables
or vice versa. The optimal treatment regime based on variables selected via
joint model is more comprehensive and reliable. With the proposed stop-
ping criteria, our method can handle a large amount of covariates even if
sample size is small. Simulation results show our method performs well in
practical settings. We further applied our method to data from a clinical
trial for depression.
Keywords and phrases: optimal treatment regime, qualitative interac-
tion, variable selection.
1. Introduction
Personalized medicine is emerging as a new strategy for treatment which takes
individual heterogeneity in disease severities, background characteristics, clini-
cal measurements and genetic information into consideration. In this paradigm,
treatment duration, dose and type are adjusted over time and tailored accord-
ing to an individual’s information, aiming to optimize the effectiveness of treat-
ment. This is different from the traditional “one-size-fits-all” treatment, which
ignores the long-term benefits and individual heterogeneities. Great interest lies
in finding optimal treatment regimes based on data from clinical trials and ob-
servational studies (e.g. Murphy, 2003; Robins, 2004; Moodie, Richardson and
Stephens, 2007).
An optimal treatment regime could involve one treatment decision or a se-
quence of treatment decisions at multiple stages. The latter one is referred to
as the optimal dynamic treatment regime, which is a sequence of decision rules
tailored through time to individual’s information, and will maximize the fi-
nal expected response when implemented. A large number of works have been
developed to derive optimal dynamic treatment regimes based on data from
clinical trials and observational studies. For example, marginal structure mod-
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els (Robins, 1997; Murphy, Van Der Laan and Robins, 2001) allow estimation
of the mean response under a dynamic treatment regime. Q-learning (Watkins,
1989; Watkins and Dayan, 1992; Murphy, 2005; Zhao et al., 2011; Chakraborty,
Murphy and Strecher, 2010; Song et al., 2011) and A-learning (Murphy, 2003;
Robins, 2004) are two popular backward induction methods for deriving op-
timal dynamic treatment regimes: the former builds regression models for the
so-called Q functions while the latter is based on modeling contrast functions.
More recently, Zhang et al. (2012) proposed a value-function based optimization
algorithm to find the best treatment regime in a specified class of treatment de-
cision rules based on the inverse propensity score weighted (IPSW) estimation of
the value function. They further extended the method to an augmented IPSW
estimation, which enjoys the double robustness property. Zhao et al. (2012) pro-
posed an outcome-weighted learning method, recasting the estimation method
of Zhang et al. (2012) in a classification framework, and developed an outcome
weighted support vector machine to estimating optimal treatment regimes.
In practice, the sequential multiple assignment randomized trial (SMART) is
an experimental design useful for deriving optimal dynamic treatment regimes
(Murphy, 2005; Qian, Nahum-Shani and Murphy, 2013). The SMART designs
have been used for some chronic or relapsing diseases. Examples include the
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (Fava
et al., 2003; Rush et al., 2004), the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) for treatment of Alzheimer’s disease (Schneider et al.,
2001) and the psychosocial treatments study for Attention Deficit Hyperac-
tivity Disorder (ADHD) in children and adolescents (Pelham Jr, Wheeler and
Chronis, 1998). As our ability to collect individual’s information is growing,
there are more and more covariates measured and available in clinical studies.
For example, a clinical trial may collect a large amount of information on pa-
tient’s demographics, medical history, intermediate outcomes and side effects.
However, it may be expensive or time-consuming to collect all these information
in clinical practice, and redundancy in covariates information may impair the
accuracy of optimal treatment decisions as well as the interpretations. Hence
a natural problem for finding optimal treatment regimes is to select important
covariates that could facilitate us to make treatment decisions.
Our work is motivated from the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) study. The STAR*D study is a randomized multistage
clinical trial of patients with nonpsychotic major depressive disorder. As there
are a lot of antidepressant medications but not a single treatment is univer-
sally effective, this study aims to determine which treatment strategies, in what
order or sequence, provides the optimal treatment effect. However, there are
a large amount of covariates collected at baseline, including patient’s demo-
graphic characteristics, medical history, etc. For treatments at the second level
and higher, there are also lots of intermediate medical measurements that are
available for making the treatment decisions at next level. It’s hard to select
covariates useful for making treatment decisions from such a large amount of
covariates based on expert opinion only, hence variable selection for identifying
the optimal treatment regime is needed.
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Variable selection is an important area in modern statistical research. How-
ever, current variable selection techniques focused on selecting variables relevant
for prediction, which may not be suitable for selecting variables relevant for de-
cision making. Variables that are vital for decision making may be neglected
by techniques targeting on prediction due to the small predictive abilities of
the interactions of these variables with treatment. In medical decision-making
setting, Gunter, Zhu and Murphy (2011) distinguished between predictive vari-
ables, which help to increase accuracy of estimator, and prescriptive variables,
which facilitate prescription of optimal treatment regimes. A prescriptive vari-
able must have qualitative interaction with treatments, that is, treatment effects
change direction when the value of this variable varies. Our goal of this paper is
to develop a variable selection method to identify prescriptive variables for im-
plementing optimal treatment regimes, especially when the number of covariates
is large.
Scarce research have been carried out to study the variable selection tech-
niques for decision making. Qualitative interaction tests (Gail and Simon, 1985;
Piantadosi and Gail, 1993; Yan, 2004) have been used to test a small number of
expert determined pre-specified interactions. However, many of the tests were
designed for testing only qualitative interactions between categorical variables
and treatments. Moreover, when the number of covariates is large these tests
are too conservative when controlling the error rate for multiple testing. Penal-
ized methods have also been studied to identify variables important for making
treatment decisions. Qian and Murphy (2011) developed a two-stage procedure
in the framework of Q-learning, where they first estimated the conditional mean
response using L1 penalized least squares, and then derived the estimated opti-
mal treatment regime from estimated conditional mean. The use of L1 penalized
least squares leads to estimated optimal treatment regimes with fewer variables
needed. Lu, Zhang and Zeng (2013) proposed a penalized least squares regres-
sion framework to select important variables for making treatment decisions,
which corresponds to a form of A-learning. Shrinkage penalties were incorpo-
rated on the interaction terms such that variables relevant to decision making
were selected. However, both of these penalized methods do not directly target
on selecting prescriptive variables, and hence may be inappropriate for select-
ing variables that are important for decision making. Gunter, Zhu and Murphy
(2011) proposed variable selection methods for qualitative interactions, where
two variable-ranking quantities were presented. These quantities characterize
qualitative interactions, which depend on two factors: the magnitude of inter-
action and the proportion of patients for whom the optimal treatment changes
given the knowledge of the variable. However, these quantities may identify too
many covariates as the potential prescriptive variables when there are a large
number of covariates. Also these quantities examine the effect of each variable
individually, which may ignore the correlation between covariates and thus lead
to identification of spurious variables or miss some important prescriptive vari-
ables for decision making.
In this paper, we proposed a new sequential advantage variable selection
method. Our goal is to select variables with qualitative interactions to derive
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the optimal treatment regime, but our method is based on sequential advantage,
which is the additional improvement of the value based on the estimated opti-
mal treatment regime with a new variable included. This sequential advantage
selection method takes variables already in the model into account and judge
whether to include a new variable or not by the additional information provided
by this variable on decision making. As our method selects relevant variables
sequentially, it can handle a large number of covariates even if the sample size
is small. Another merit of the sequential selection procedure is that it does not
include those variables which are marginally important but jointly unimportant
and hence avoids redundant information in the model for decision making. We
also proposed a stopping criteria based on proportion of incremental sequential
advantages to decide how many variables to be included for decision making.
The paper is organized as follows. In Section 2 we introduce the framework
for identifying optimal treatment regimes, and the S-score method for select-
ing prescriptive variables. Section 3 provides the proposed sequential advantage
selection for variable selection in optimal treatment decision making. We demon-
strate their performance in Section 4 by simulation studies in various scenarios,
and illustrate these methods using data from the STAR*D clinical trial in Sec-
tion 5.
2. Variable Selection for Optimal Treatment Regime
2.1. Optimal Treatment Regime
Consider a clinical trial or an observational study where point exposure treat-
ments are given to n subjects sampled from the population of interest, and
assume that there are two possible treatment options assigned to each sub-
ject. Denote A as the treatment and assume possible values of A are coded
as {0, 1}, which is in accordance with two treatment options. We aim to find
the optimal treatment regime based on p−dimensional covariates of a subject
X = (X1, X2, ..., Xp)
T . Following a treatment A given to the subject, a response
Y could be obtained. Suppose larger response is preferred. The observed data
can be summarized as (Xi, Ai, Yi), i = 1, ..., n, where Xi = (Xi1, ..., Xip)
T . A
treatment regime d(X) is a mapping from X , the space of covariates X, to A,
the space of action A. Our goal is to find the treatment regime dopt(X) that can
maximize the expected mean response.
In this context, we want to identify the optimal treatment regime mapping
from X to {0, 1}. To put it formally, we need to introduce potential outcomes
Y ∗(1) and Y ∗(0), which are the outcomes that would be observed if a subject
is assigned to treatment 1 or 0. With the concepts of potential outcomes, an
optimal treatment regime can be defined as dopt(X) = argmaxd∈D E[Y ∗(d(X))],
where D is the collection of all possible treatment regimes, i.e., all possible
mappings from X to A.
Two assumptions are essential to make identifying optimal treatment regimes
possible. First is the stable unit treatment value assumption (Rubin, 1978):
A. Fan et al./SAS for Optimal Treatment Regimes 5
Y = I(A = 0)Y ∗(0) + I(A = 1)Y ∗(1). That is, an individual’s outcome is the
same as the potential outcome for the assigned treatment, and is not influenced
by other individuals’ treatment allocations. Second is the no unmeasured con-
founders assumption: {Y ∗(0), Y ∗(1)} ⊥ A|X, i.e., the treatment assignment is
independent of the potential outcomes conditional on observed covariate infor-
mation (Robins, 1997). With these two assumptions, it is straightforward to
show that
E[Y ∗(d(X))] = EX {E(Y |X, A = 1)d(X) + E(Y |A = 0,X)[1− d(X)]} ,
that is, E[Y ∗(d(X))] can be expressed by the observed data. Hence the optimal
treatment regime could be derived as:
dopt(x) = argmax
a∈A
E(Y |X = x, A = a).
That is, for each possible value of covariate X, we’ll find the treatment a that
maximizes the expected response. Because the distribution of (X, A, Y ) is un-
known in practice, we could only estimate E(Y |X = x, A = a) given a posited
model based on the observed data.
2.2. S-Score Method
When there are a large amount of covariates, only some of the covariates need
to be considered in the model E(Y |X = x, A = a) as independent predictors
for making optimal treatment decision. Gunter, Zhu and Murphy (2011) men-
tioned that current variable selection techniques pay more attention to selecting
the predictive variables, but are likely to neglect some important prescriptive
variables. Parmigiani (2002) proposed value of information using the experimen-
tal outcome to help evaluating the treatment effect. Gunter, Zhu and Murphy
(2011) proposed S-score based on the value of information, which is a quantity
of a variable that characterizes the degree of qualitative interaction. The rank-
ing of S-scores shows the ranking of possibilities of different covariates to be
prescriptive variables. To put it formally, the S-score for a univariate covariate
Xj , j = 1, ..., p, is defined as:
Sj =
n∑
i=1
{
max
a
[Eˆ(Y |Xj = xij , A = a)]− Eˆ(Y |Xj = xij , A = aˆ)
}
. (1)
Here Eˆ(Y |Xj = xij , A = a) is an estimator of E(Y |Xj = xij , A = a), the
expected response of Y given covariate Xj and treatment A, and aˆ is the opti-
mal treatment regime without considering the effect of the covariates, that
is, aˆ = argmaxa Eˆ(Y |A = a). For example, if the model for E(Y |Xj , A) is
E(Y |Xj , A) = β0 + β1Xj + β2A + β3XjA, then (β0, β1, β2, β3)T can be esti-
mated by the least squares estimates, denoted as (βˆ0, βˆ1, βˆ2, βˆ3)
T . S-score for
Xj then has the following expression:
Sj =
n∑
i=1
(βˆ2 + βˆ3xij)
[
1(βˆ2 + βˆ3xij ≥ 0)− aˆ
]
. (2)
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We note that Sj is always non-negative. The first and second terms of Sj in
(1) are obtained based on the same model of Y given covariate Xj and treatment
A, but the first term adopts the optimal treatment based on the posited model
for E(Y |Xj = xij , A = a), while the second term adopts the optimal treatment
based on no covariate information. Hence only the interaction term of those
individuals whose optimal treatment based on Xj is different from the optimal
treatment aˆ that based on no covariate information will give a contribution to
the S-score. As stated in Gunter, Zhu and Murphy (2011), the S-score captures
both the magnitude of interaction and the proportion of subjects whose opti-
mal treatment changes. For example, in equation (2), (βˆ2 + βˆ3xij) stands for
the treatment effect, which depicts the magnitude of the interaction between
the variable Xj and the treatment A, and
[
1(βˆ2 + βˆ3xij ≥ 0)− aˆ
]
stands for
the proportion of patients whose optimal treatment changes given knowledge of
the variable Xj . Therefore both these two factors are reflected in S-score, which
makes S-score a good quantity that characterizes the degree of qualitative in-
teractions.
3. Sequential Advantage Selection
S-score characterizes qualitative interaction of each individual covariate, which
helps to find prescriptive variables for deriving optimal treatment regimes. How-
ever, there are some limitations with the S-score method. First, when the number
of covariates is very large, the S-score method tends to select many variables
with no qualitative interactions with the treatments since their S-scores are
nonzero due to the correlations among covariates. Second, since each variable is
evaluated individually with the S-score method, some variables that are jointly
crucial for optimal treatment decision making may be neglected by the S-score
method, because the S-score method does not take correlations between vari-
ables into account. We are thus motivated to consider sequential selection based
on modified S-scores, which calculates the conditional marginal S-scores for each
covariate sequentially with the variables previously included in the model. The
new quantity to evaluate each covariate is called sequential advantage.
For convenience, we use M = {j1, .., jk} to denote an arbitrary model with
Xj1 , ..., Xjk as the selected covariates. Let F = {1, ..., p} denote the full model.
Xi is the covariate for ith subject and Xi(M) = {Xij : j ∈ M} is the covari-
ate for ith subject corresponding to model M. The sequential advantage of a
variable Xj with k − 1 variables Xj1 , ..., Xjk−1 already in the model is defined
as:
S
(k)
j =
1
n
n∑
i=1
{
max
a
Eˆ(Y |XM(k)j = xiM(k)j , A = a)
−Eˆ(Y |XM(k)j = xiM(k)j , A = a
(k−1)
opt (xiM(k−1)))
}
,
where M(k−1) = {j1, ..., jk−1}, M(k)j = M(k−1) ∪ {j}, and ak−1opt (xiM(k−1))
is the optimal treatment regime based on k − 1 variables Xj1 , ..., Xjk−1 . This
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sequential advantage is similar to that in equation (1), but the model of the
mean response E(Y ) is based on the current variable Xj and all the variables
that are selected before the kth step. Here Eˆ(Y |XM(k)j = xiM(k)j , A = a) is
an estimator of the mean response of Y given all the available covariates at
this step XM(k)j
and treatment A. In practice, a linear model with main effects
of XM(k)j
and A, and interaction effects between XM(k)j
and A can be used
to model Eˆ(Y |XM(k)j , A). This quantity shows the additional advantage of the
variable Xj for improving the optimal treatment decision. Sequential selection
guarantees that no redundant variables are included in the decision-making
model and leads to a joint model for obtaining the optimal treatment regime.
In the sequential advantage selection, we provide a stopping rule based on the
proportion of the incremental sequential advantage. Below is the algorithm of
sequential advantage selection for decision making.
Step 1 (Initialization). Let M(0) = ∅. First compute
a
(0)
opt = argmax
a
Eˆ(Y |A = a). (3)
Let
S(0) = Eˆ(Y |A = a(0)opt)− {piEˆ(Y |A = 1) + (1− pi)Eˆ(Y |A = 0)}, (4)
where pi is the probability of assigning a patient treatment 1 in the study. Here
S(0) is a quantity of total gain in outcome by using the optimal treatment
a
(0)
opt rather than randomly assigning treatments to patients. This is a baseline
advantage increment, and will be used as a reference in the stopping criteria.
Step 2 (Sequential Advantage Selection). In the kth step (k ≥ 1), we have
M(k−1). For every j ∈ F \M(k−1), we consider candidate covariates M(k)j =
M(k−1) ∪ {j} and compute the sequential advantage V corresponding to jth
covariate in kth step. The kth variable to be selected is the one with the largest
sequential advantage in this step, that is:
jk = argmax
j∈F\M(k−1)
{S(k)j }. (5)
Update M(k) = M(k−1) ∪ {jk}. The optimal treatment regime that based on
the first k variables XM(k) is also updated accordingly:
a
(k)
opt (XS(k)) = argmax
a
Eˆ(Y |XS(k) , A = a). (6)
Let S(k) = S
(k)
jk
, which is the sequential advantage increment based on the kth
selected variable.
Step 3 (Stopping Criteria). Iterate Step 2 until we get the sequence Sp∗ =
{j1, ..., jp∗}, where p∗ is the first l ∈ {0, 1, .., p} that satisfies propl ≥ c and
propl+1 < c. Here propl stands for the proportion of the incremental sequential
advantage and is defined as:
propl =
S(l)∑l
i=0 S
(i)
, l = 0, 1, ..., p, (7)
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with propp+1 = 0. This quantity characterizes the proportion of the additional
advantage of the lth selected variable to sum of all the sequential advantages
explained by the lth selected variable and all previously selected variables. Here
c is a cut-off point for the proportion of the incremental sequential advantage.
We choose c = 0.01, that is, if a newly selected variable could only explain less
than 1% of the information explained by currently total selected variables, we
will not include this variable and stop. If prop1 < c, then p
∗ = 0, which means
we will not include any variable in the model. The variables (j1, ..., jp
∗
)t are
the selected important prescriptive variables to make treatment decisions, and
a
(p∗)
opt (XM(p∗)) is the optimal treatment regime for the corresponding model.
4. Simulations
To test performance of the proposed method on variable selection and the accu-
racy of estimating the decision rule, we compared sequential advantage selection
(SAS) with S-score method in Gunter, Zhu and Murphy (2011) and the method
proposed by Lu, Zhang and Zeng (2013) under various settings. Although S-score
has a natural ranking of the covariates, it doesn’t provide an optimal treatment
regime based on the variables selected. For fair comparison, we handle S-score
method in two ways: one is to include all variables with non-zero S-scores and
to see whether they include the true important variables; the other is to include
the same number of variables as that of SAS method based on S-score ranking
and to fit a new linear model with these variables to get the optimal treatment
regime. The method proposed by Lu, Zhang and Zeng (2013) adopts LASSO
type shrinkage penalties on a least squares loss function, which has a form of
A-learning and thus does not rely on the correct specification of the baseline
function. As done in Lu, Zhang and Zeng (2013), we use the sample mean of
responses Y as the baseline function in A-learning here, and the LASSO penalty
for variable selection. We refer this method as LASSO in simulation results. The
tuning parameter λ of the LASSO method is chosen by cross validation. The
LASSO method and its cross validation is implemented using R-package glmnet.
In our simulation settings, we considered both randomized studies and obser-
vational studies with confounders that are not relevant variables for decision
making.
For each simulation data set, we generated n = 200 observations (Xi, Ai, Yi),
i = 1, ..., n, where Yi is the response variable, Ai is the treatment assigned to
ith patient whose possible value is {0, 1}, and Xi is a column vector containing
p = 1000 independent variables. LetXn×p = (X1,X2, ...,Xn)T , and X˜n×(p+1) =
(1n×1,X). We consider the following three models to generate simulation data,
which have linear form of covariates for the interaction with treatment, and
different function forms for the baseline:
• Model I: Y = 1 + γT1 X+AβT X˜+  with γ1 = (1,−1,0p−2)T .
• Model II: Y = 1+0.5(γT1 X)(γT2 X)+AβT X˜+ with γ1 = (1,−1,0p−2)T , γ2 =
(1,02,−1,05, 1,0p−10)T .
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• Model III: Y = 1 + 0.5sin(piγT1 X) + 0.25(1 + γT2 X)2 +AβT X˜+  with γ1
and γ2 being the same as in Model II.
Here covariates Xi = (Xi1, ..., Xip)
T are generated from a multivariate normal
distribution. Each entry is normal with mean 0, variance 1, and the correlation
between covariates is Corr(Xij , Xik) = ρ
|j−k|, for j 6= k, j, k = 1, ..., p. In our
simulations, we used linear models with main effects of covariates and treatment
as well as interaction effects between covariates and treatment to model the re-
sponse Y given some covariates and treatment. Hence the fitted models in SAS
procedure are eventually correctly specified when the true model is Model I, but
the main effect parts of the models are misspecified when the true models are
Model II and III. To examine the performance with different correlations be-
tween covariates, ρ is chosen to be 0.2, 0.5 and 0.8 to represent weak, moderate
and strong correlations respectively. The error term  is normally distributed
with mean zero and variance 0.25.
Based on these models, the optimal decision will be I(βT X˜ ≥ 0), hence im-
portant variables for decision making are those whose corresponding coefficient
βj 6= 0. We consider two sets of values for β:
• β0 = 0.1, β1 = 1, β9 = −0.9, β10 = 0.8, other βj ’s are zero.
• β0 = 0.1, β1 = 1, β9 = −0.9, β10 = 0.8, β20 = 0.8, β22 = 1.5, β30 =
−2, β35 = 2, β40 = 3, other βj ’s are zero.
In the first scenario, there are 3 important prescriptive variables: X1, X9 and
X10, which we refer to as sparse true model. In the second scenario, there are
8 important prescriptive variables: X1, X9, X10, X20, X22, X30, X35 and X40,
which we refer to as less sparse true model. As the generative models are com-
plex, it becomes rather difficult to evaluate the degree of marginal qualitative
interaction of each variable with treatment by the absolute value of β due to
the correlation between covariates. As an illustration, we show in Figure 1 the
marginal interaction plots of variables, X1, X9 and X10 with treatment under
two choices of correlation between covariates: ρ = 0.2 and ρ = 0.8, which are
shown in the left and right panel of Figure 1 respectively. These marginal plots
are from one simulation under model I with the first choice of β. The coefficients
for the interaction terms of X1, X9 and X10 with treatment A are 1, -0.9 and
0.8. Based on Figure 1, it can be seen that the qualitative interaction effects
for one of the variables X9 and X10 become weak due to the high correlation
between these two variables and the opposite effects of these two variables.
In the simulation settings, we consider both scenarios of randomized studies
and observational studies. In the randomized study, the treatment is assigned to
each patient randomly with P (A = 1) = P (A = 0) = 1/2. In the observational
study, the treatment is assigned to each patient with logit{P (A = 1)} = −0.2 +
0.8X21 + 0.8X
2
29, where logit(u) = log{u/(1− u)}.
We implement SAS, S-score and the LASSO methods on each simulated data
set with 500 replications. To evaluate the performance of these three methods,
we compare them in two aspects. For variable selection, we recorded the average
number of variables selected by each method. We also reported true discovery
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rate (TDR), the proportion correctly identified important variables among all
the selected variables, and true positive (TP), the number of correctly identified
important variables. For accuracy of estimated optimal treatment regimes, we
evaluated the true mean response following the estimated optimal treatment
regime gˆopt of the three methods, as well as the error rate of the estimated
optimal treatment regime compared to the true optimal treatment regime. The
true value of an estimated treatment regime is estimated by the average outcome
of Monte Carlo simulation with 10,000 replicates. Simulation results are shown
in Tables 1, 2, 3 and 4, where Tables 1, 3 are results for variable selection and
Tables 2 , 4 are for results for estimation of optimal treatment regimes.
We summarize the observations as follows. First, S-score method seems to
always select too many variables if all covariates with non-zero S-scores are
included. Under weak and moderate correlations, i.e. ρ = 0.2 or 0.5, the LASSO
method tends to select a few more variables than SAS method in models I and
II when the true models are sparse, and selected much more variables than SAS
method when the true models are less sparse. What’s more, standard deviations
of the number of variables selected by SAS method are small, which shows
stability of SAS method. As the correlation increases, the average true positives
for all three methods gets lower, which is reasonable as there are less information
provided by highly correlated covariates. SAS method is capable to include
more important variables than the S-score method and LASSO method in all
simulation settings. When the true model is sparse, SAS method can recover
almost all the important variables under weak and moderate correlations with
small variances of the true positives.
The true discovery rates depend on both the number of variables selected and
the ability to identify important variables. When the true models are sparse,
the TDRs of SAS method are not very high especially under moderate to high
correlations. However, for the cases where the true models are less sparse, which
are shown in Table 3, the TDRs of SAS method are relatively high because the
size of variables selected is small, and are much higher than those of S-score and
the LASSO methods.
According to Table 2 and Table 4, SAS method provides a good estimate
of optimal treatment regime with values close to the values obtained by imple-
menting the true optimal treatment regime and low error rates, especially in the
case of model I. The error rates of S-score method are slightly higher than those
of SAS method in most cases. The error rates provided by the LASSO method
are approximately 0.4 in most cases. Despite that the LASSO method could
select some important variables, the estimated optimal treatment regime did
not provide accurate decision rules partly because the LASSO estimates tends
to have big bias due to shrinkage. In Table 4 when the true decision rule is less
sparse, the values of estimated optimal treatment regimes of SAS method are
the closest to the true optimal values among the three methods in all cases. In
Table 2 when the true decision rule is sparse, the values of estimated optimal
treatment regimes of the LASSO method are larger than those of SAS method
in some cases with Model II and Model III, even if the error rates of the LASSO
method are higher. This may be because the values in the cases with only three
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important variables are not sensitive to treatment regimes, hence a treatment
regime that is not close to the optimal treatment regime could still lead to a
high value. However, in the case with eight important variables as shown in
Table 4, as the magnitudes of the nonzero coefficients β are larger, treatment
regimes that are far from the optimal treatment regime could get values much
lower than the optimal value.
We also compare solution paths of three methods to evaluate their selection
performance. Here we define the solution path as the trajectory of the number
of identified important interaction variables as the numbers of selected variables
increases according to the selection order. For demonstration purpose, we only
plot the solution paths for the first 30 selected variables. SAS method has a
natural order of selected variables. For S-score method, we ranked the variables
by the descending order of S-scores of these variables. The LASSO method has
a solution path of β, which can be used to determine the order of variables
entering the model. The solution path plots allow us to evaluate the ability
of each method to identify important variables given that the same number of
variables is selected. These plots are given in Figure 2, 3, 4 and 5 under different
simulation settings.
As shown in Figures 2–5, when the number of variables included in the model
for each method is fixed, SAS method includes the largest number of impor-
tant variables in most cases. When the data are generated under model I, SAS
method can include all the important variables in a small number of steps when
ρ is not too large. When ρ is large, as the two important variables 9 and 10
are highly correlated, they are likely to be missed by all the three methods,
while SAS method still has the highest probability of including these two vari-
ables. When the data are generated under model II and model III, all of the
methods used the mis-specified models to fit the data and the performance on
variable selection is not as good as those in model I. However, SAS method still
outperforms other two methods. As the LASSO method is implemented in the
framework of A-learning which is robust to baseline function mis-specification,
it seems to suggest that SAS method also embraces this robustness.
Overall, SAS method performs well on both the aspect of variable selection
and the aspect of estimating optimal treatment regime. SAS method can select
most important variables at a moderate size of the set of selected variables.
When the model is correctly specified and the correlations between covariates
are not too high, the SAS method is able to identify all important variables.
The error rates of the optimal treatment regime based on SAS method are low
and the estimated values are close to the truth. While the S-score and LASSO
methods have their appeal in some cases, SAS method is also competitive in
these cases and is more advantageous considering its ability to identify important
variables for decision making.
5. Application to STAR*D Study
We apply the proposed method to data from STAR*D Study, which was con-
ducted to determine the effectiveness of different treatments for patients with
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major depressive disorder (MDD) who have not been adequately benefiting from
initial treatment with an antidepressant. There are 4041 participants (age 18-
75) with nonpsychotic MDD enrolled in this study. Initially these participants
were treated with citalopram (CIT) up to 14 weeks. Subsequently, 3 more levels
of treatments were provided for participants without a satisfactory response to
CIT. At each level, participants were randomly assigned to treatment options
acceptable to them. At Level 2, participants are eligible for seven treatment op-
tions, which may be conceptualized as two treatment strategies: medication or
psychotherapy switch, and medication or psychotherapy augmentation. Avail-
able treatments for participants elected to switch are: sertraline (SER), ven-
lafaxine (VEN), bupropion (BUP) and cognitive therapy (CT); available treat-
ments for patients elected to augment are: augmenting CIT with bupropion
(CIT+BUP), buspirone (CIT+BUS) or cognitive therapy (CIT+CT). Partici-
pants without a satisfactory response to CT were provided additional medication
treatments which is called Level 2A. All participants who did not respond satis-
factorily at Level 2 or 2A were eligible for Level 3, where possible treatments are
medication switch to mirtazapine (MIRT) or nortriptyline (NTP), and medica-
tion augmentation with either lithium (Li) or thyroid hormone (THY). Partici-
pants without satisfactory response to Level 3 were re-randomized at Level 4 to
either tranylcypromine (TCP) or a combination of mirtazapine and venlafaxine
(MIRT+VEN). Participants who respond satisfactorily were followed up to 1
year. See Fava et al. (2003) and Rush et al. (2004) for more detailed description
of this STAR*D design.
For illustration, we focused on comparing treatment BUP and SER within
subset of participants who agreed to be randomized within medication switch
at Level 2. Our goal is to identify relevant prescriptive predictors and estimate
the optimal treatment decision within this sub group. Possible relevant covari-
ates include participant features such as age, gender, socioeconomic status, and
ethnicity, illness features such as medication history, family history of mood
disorders, and care features such as clinician type. Intermediate medical con-
ditions from Level 1 such as degree of symptom improvement and side effect
burden are also considered. Table 5 lists all of the 305 covariates considered
to make treatment decision. Symptomatic status was measured by the 16-item
Quick Inventory of Depressive Symptomatology - Clinician-Rated (QIDS-C16).
Because low QIDS-C16 stands for remission, we use negative QIDS-C16 as our
final outcome. There are 319 participants who had complete records of covari-
ates and final outcomes within medication switch substrategy group that had
been randomly assigned to treatment BUP or SER. Among these participants
153 were treated with BUP and 166 were treated with SER.
We applied the three methods, SAS, S-score and the LASSO method con-
sidered in simulations to this real data set. The variable selection results are
as follows. The LASSO method doesn’t select any variable for treatment de-
cision. S-score method had 219 variables with non-zero S-scores. SAS method
selected 33 variables with cut-off point in the stopping criteria as 0.01. The rea-
son that the LASSO method didn’t include any variables is probably that these
covariates could not provide a good prediction on the response. It is reasonable
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as most of the covariates are categorical, which doesn’t include much informa-
tion about the response. The S-score method selects a lot of covariates, which
indicates that there are potentially some prescriptive variables among these co-
variates. SAS method includes a moderate size of covariates as the important
variables, which provides a guidance to clinicians on the covariates that have
an effect on treatment decision making. The optimal treatment regime based on
SAS method assign 155 patients to treatment BUP, and the rest 164 patients to
treatment SER. Among these 33 variables, 10 of them are related to the answers
in psychiatric diagnostic screening questionnaire, 5 of them are about rating of
depression, 2 of them are QIDS-C and QIDS-SR score changing rates at Level 1,
7 of them are related to patient rated inventory of side effects. The rest 9 vari-
ables are demographic factors of the patients. Both covariates at baseline and
at Level 1 are selected. For selected covariates at baseline, there are covariates
related to both the patient’s features and illness features; For selected covariates
at Level 1, which are intermediate covariates, there are covariates related to the
depression changing rate after the first treatment is given, as well as the side
effects of the treatment at Level 1. Hence the optimal treatment decision at
Level 2 depends on a comprehensive examination of patient’s situation at both
baseline and Level 1.
To further examine the variables selected by SAS method, we evaluate the
values obtained following the estimated optimal treatment regime based on these
selected variables. The average value of a treatment regime is estimated by
inverse probability weighted estimator used in Zhang et al. (2012), defined as
IPW = 1n
∑n
i=1
YiI(Ai=g(Xi))
pi(Ai)
. Here g(Xi) is the estimated treatment regime, and
pi(Ai) is the probability of receiving treatment Ai. As the LASSO method didn’t
include any variables, we want to compare the estimated value for the estimated
optimal treatment regime of SAS method to the values we get when all subjects
are treated with the same treatment, that is, the treatment regime based on no
covariate. The estimated value for SAS method is -7.84, and the estimated values
with treatment BUP and SER are -10.74 and -10.52, respectively. To examine
whether the difference between the value based on SAS method and the value
with one treatment only is significantly different from 0, we used 1000 bootstrap
sample to obtain the confidence interval for the differences of values. The 95%
bootstrap confidence interval for the value difference between SAS method and
BUP treatment is (0.74, 5.15), and the 95% bootstrap confidence interval for
the value difference between SAS method and SER treatment is (0.37, 4.82). As
both confidence intervals don’t include zero, it suggested that the value using
optimal treatment regime based on SAS method is better than the values based
on one treatment only.
6. Discussion
In this article, we proposed a variable selection method for optimal treatment
decision making, which targets prescriptive variables that are important for
decision making and selects variables in a sequential procedure such that the
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variables selected contain no redundant information. We provided a stopping
criteria such that our final decision-making model can provide enough infor-
mation with a small number of variables. Our method can be applied to data
with continuous outcomes and binary treatment options from a clinical trial
or an observational study. Simulation studies demonstrated that our method
could identify most important variables under various settings, and provide a
good estimated optimal treatment regime that has a small error rate and a high
average outcome value.
Gunter, Zhu and Murphy (2011) proposed a hybrid algorithm that combines
the LASSO selection and S-score ranking. Specifically, it first uses the LASSO
method to select both important predictive and prescriptive variables, and then
uses the S-score method to rank the selected variables for making treatment
decision rules. Similarly, SAS method can also be combined with the LASSO
method to provide a comprehensive algorithm for variable selection. What’s
more, in the stopping criteria we proposed, we can tune the cut-off point c using
data to achieve the goal of maximizing the expected outcome of the treatment
regime.
The proposed method is applicable to the case with more than two treatment
options. It may be extended to the situation where the outcome is categorical or
censored by appropriately modeling the expected outcome given the covariates
and the treatment. Moreover, since dynamic treatment with multiple decision
points is common for chronic disease, it is desirable to extend our method to
the dynamic treatment regime with multiple stages.
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Fig 1. Illustration of qualitative interactions of the covariates X1, X9 and X10 with treatment
A. These are marginal plots of response Y versus covariates X1, X9 and X10 (from top to
bottom) in two different treatment groups, treatment 1 and treatment 0 from one simulation
based on model I and the first choice of β. Correlations between covariates are: ρ = 0.2 (left
panel) and ρ = 0.8 (right panel). The fitted lines are from simple linear regression based on
data from one treatment group. Black triangles and dashed lines are from treatment 1, and
red circles and dotted lines are from treatment 0.
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Table 1
Results on variable selection of sequential advantage selection (SAS), S-score and LASSO
methods for the scenarios with the first choice of β (three important prescriptive variables:
X1, X9 and X10). Size is the number of covariates selected. For S-score method, Size S 6= 0
is the number of covariates with nonzero S-scores. TDR stands for true discovery rate,
which is the proportion correctly identified important variables among all the selected
variables. TP stands for true positive, which is the number of correctly identified important
variables among X1, X9 and X10. The quantity in parenthesis is standard deviation of
corresponding value.
Setting
SAS S-score LASSO
Size TDR TP Size S 6= 0 TDR TP Size TDR TP
Randomized Study
Model I, ρ = 0.2 7.67 0.42 2.98 765.28 0.23 1.66 17.40 0.211 1.60
(2.71) (0.09) (0.23) (163.13) (0.11) (0.68) (23.29) (0.29) (1.05)
Model I, ρ = 0.5 9.55 0.34 2.92 757.18 0.16 1.35 15.04 0.24 1.37
(2.91) (0.11) (0.38) (165.78) (0.08) (0.51) (18.61) (0.31) (0.79)
Model I, ρ = 0.8 14.05 0.17 2.05 738.44 0.08 1.09 11.44 0.28 1.10
(3.68) (0.11) (1.00) (173.40) (0.03) (0.28) (14.29) (0.30) (0.44)
Model II, ρ = 0.2 23.08 0.12 2.58 762.73 0.11 2.43 23.42 0.22 2.32
(3.87) (0.04) (0.76) (169.38) (0.04) (0.62) (25.22) (0.23) (0.86)
Model II, ρ = 0.5 22.16 0.12 2.41 747.08 0.09 1.88 20.54 0.25 1.91
(4.32) (0.06) (0.89) (176.22) (0.04) (0.57) (23.56) (0.28) (0.84)
Model II, ρ = 0.8 17.44 0.12 1.91 721.28 0.07 1.19 12.93 0.27 1.29
(4.56) (0.08) (0.98) (188.22) (0.04) (0.40) (15.93) (0.27) (0.58)
Model III, ρ = 0.2 22.58 0.11 2.35 765.27 0.09 1.98 15.84 0.20 1.48
(4.32) (0.06) (1.04) (165.52) (0.04) (0.71) (21.65) (0.28) (1.02)
Model III, ρ = 0.5 23.27 0.09 2.04 758.89 0.07 1.46 13.36 0.20 1.10
(4.04) (0.06) (1.02) (169.00) (0.03) (0.57) (22.14) (0.29) (0.83)
Model III, ρ = 0.8 22.75 0.08 1.66 749.84 0.05 1.17 11.65 0.22 0.98
(4.27) (0.05) (0.88) (170.04) (0.02) (0.40) (15.26) (0.28) (0.50)
Observational Study
Model I, ρ = 0.2 8.44 0.38 3.00 760.58 0.22 1.73 34.43 0.14 2.94
(2.13) (0.09) (0) (158.94) (0.11) (0.71) (24.72) (0.13) (0.25)
Model I, ρ = 0.5 9.51 0.35 2.99 760.74 0.15 1.36 36.43 0.16 2.71
(2.89) (0.11) (0.15) (164.11) (0.08) (0.57) (27.92) (0.20) (0.58)
Model I, ρ = 0.8 12.46 0.21 2.28 746.41 0.10 1.11 17.63 0.28 1.62
(3.67) (0.12) (0.96) (167.70) (0.04) (0.31) (21.87) (0.31) (0.64)
Model II, ρ = 0.2 19.58 0.15 2.84 527.97 0.13 2.42 28.30 0.18 2.96
(4.07) (0.05) (0.50) (207.27) (0.05) (0.64) (22.26) (0.15) (0.21)
Model II, ρ = 0.5 18.91 0.15 2.67 609.91 0.11 1.88 31.67 0.16 2.82
(4.00) (0.06) (0.72) (211.18) (0.04) (0.57) (24.06) (0.17) (0.45)
Model II, ρ = 0.8 16.62 0.14 2.08 672.87 0.08 1.25 21.04 0.25 1.82
(4.21) (0.08) (1.00) (194.65) (0.04) (0.44) (22.84) (0.28) (0.78)
Model III, ρ = 0.2 19.80 0.16 2.93 680.88 0.10 1.91 28.68 0.18 2.91
(3.93) (0.04) (0.34) (201.15) (0.05) (0.73) (23.58) (0.14) (0.33)
Model III, ρ = 0.5 20.55 0.14 2.65 704.98 0.08 1.44 27.82 0.19 2.52
(4.19) (0.06) (0.74) (199.21) (0.04) (0.63) (23.55) (0.19) (0.64)
Model III, ρ = 0.8 19.66 0.11 2.12 712.65 0.06 1.13 16.40 0.264 1.64
(4.14) (0.06) (0.96) (191.05) (0.03) (0.45) (19.08) (0.27) (0.59)
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Table 2
Estimated optimal values and error rates of sequential advantage selection (SAS), S-score
and LASSO methods for the scenarios with the first choice of β (three important
prescriptive variables: X1, X9 and X10). True value Q(gopt) is the mean response following
the true optimal treatment regime gopt, while Q(gˆopt) is the mean response following the
estimated optimal treatment regime gˆopt of the three methods. The mean response of each
optimal treatment regime is obtained by the average outcome of Monte Carlo simulation
using the true model with 10,000 replicates. Err.rate stands for error rate of the estimated
optimal treatment regime, which is the proportion of individuals with misspecified optimal
treatment following the estimated optimal treatment regime. The quantity in parenthesis is
standard deviation of corresponding value.
Setting
True Value SAS S-score LASSO
Q(gopt) Q(gˆopt) Err.rate Q(gˆopt) Err.rate Q(gˆopt) Err.rate
Randomized Study
Model I, ρ = 0.2 1.66 1.64(0.05) 0.072 1.41(0.13) 0.275 1.32(0.19) 0.436
Model I, ρ = 0.5 1.60 1.56(0.06) 0.103 1.38(0.08) 0.270 1.35(0.15) 0.449
Model I, ρ = 0.8 1.51 1.41(0.06) 0.182 1.40(0.03) 0.199 1.40(0.06) 0.473
Model II, ρ = 0.2 2.08 1.78(0.10) 0.299 1.79(0.11) 0.283 1.45(0.14) 0.460
Model II, ρ = 0.5 1.91 1.66(0.09) 0.285 1.62(0.08) 0.289 1.73(0.10) 0.466
Model II, ρ = 0.8 1.65 1.49(0.06) 0.243 1.50(0.04) 0.233 1.57(0.03) 0.484
Model III, ρ = 0.2 2.66 2.33(0.13) 0.312 2.30(0.13) 0.325 2.30(0.19) 0.432
Model III, ρ = 0.5 2.54 2.22(0.10) 0.327 2.18(0.08) 0.346 2.22(0.17) 0.442
Model III, ρ = 0.8 2.20 1.95(0.06) 0.314 1.98(0.05) 0.296 2.03(0.13) 0.459
Observational Study
Model I, ρ = 0.2 1.66 1.63(0.02) 0.100 1.43(0.12) 0.257 1.56(0.03) 0.334
Model I, ρ = 0.5 1.60 1.55(0.04) 0.125 1.43(0.07) 0.236 1.51(0.03) 0.319
Model I, ρ = 0.8 1.51 1.41(0.06) 0.190 1.41(0.02) 0.196 1.45(0.01) 0.311
Model II, ρ = 0.2 2.08 1.82(0.09) 0.286 1.83(0.11) 0.256 2.01(0.04) 0.314
Model II, ρ = 0.5 1.91 1.68(0.08) 0.278 1.66(0.08) 0.268 1.83(0.03) 0.310
Model II, ρ = 0.8 1.65 1.49(0.06) 0.251 1.51(0.03) 0.228 1.59(0.01) 0.309
Model III, ρ = 0.2 2.66 2.40(0.08) 0.289 2.35(0.13) 0.289 2.57(0.04) 0.320
Model III, ρ = 0.5 2.54 2.27(0.09) 0.303 2.23(0.09) 0.310 2.44(0.03) 0.318
Model III, ρ = 0.8 2.20 1.98(0.07) 0.301 2.01(0.06) 0.273 2.13(0.01) 0.312
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Table 3
Results on variable selection of sequential advantage selection (SAS), S-score and LASSO
methods for the scenarios with the second choice of β (eight important prescriptive
variables: X1, X9, X10, X20, X22, X30, X35 and X40). Size is the number of covariates
selected. For S-score method, Size S 6= 0 is the number of covariates with nonzero S-scores.
TDR stands for true discovery rate, which is the proportion correctly identified important
variables among all the selected variables. TP stands for true positive, which is the number
of correctly identified important variables among X1, X9, X10, X20, X22, X30, X35 and
X40. The quantity in parenthesis is standard deviation of corresponding value.
Setting
SAS S score LASSO
Size TDR TP Size S 6= 0 TDR TP Size TDR TP
Randomized Study
Model I, ρ = 0.2 8.66 0.77 6.36 775.90 0.44 3.63 32.26 0.23 4.99
(2.28) (0.17) (1.17) (166.25) (0.14) (0.80) (22.67) (0.16) (1.28)
Model I, ρ = 0.5 6.84 0.85 5.63 776.29 0.51 3.38 32.05 0.22 5.03
(1.64) (0.15) (0.84) (164.99) (0.15) (0.81) (20.32) (0.13) (1.06)
Model I, ρ = 0.8 5.91 0.86 4.98 772.77 0.29 1.68 32.80 0.19 4.80
(1.13) (0.15) (0.85) (164.44) (0.10) (0.61) (18.94) (0.11) (1.07)
Model II, ρ = 0.2 8.42 0.77 6.22 773.33 0.48 3.81 34.29 0.22 5.32
(2.22) (0.18) (1.17) (160.75) (0.15) (0.81) (22.01) (0.13) (1.20)
Model II, ρ = 0.5 6.45 0.89 5.61 776.16 0.55 3.42 34.45 0.21 5.30
(1.37) (0.13) (0.91) (163.31) (0.15) (0.81) (22.52) (0.12) (1.05)
Model II, ρ = 0.8 5.65 0.89 5.00 773.70 0.29 1.64 35.02 0.18 4.95
(0.91) (0.13) (0.79) (164.49) (0.11) (0.59) (20.24) (0.10) (1.01)
Model III, ρ = 0.2 11.07 0.59 5.94 775.56 0.38 3.82 31.92 0.23 4.91
(3.40) (0.21) (1.34) (164.35) (0.15) (0.87) (23.53) (0.15) (1.32)
Model III, ρ = 0.5 9.32 0.64 5.44 775.36 0.43 3.67 33.28 0.22 4.95
(2.92) (0.20) (1.01) (163.33) (0.15) (0.84) (24.79) (0.14) (1.19)
Model III, ρ = 0.8 6.83 0.743 4.80 774.23 0.28 1.90 31.35 0.20 4.58
(1.83) (0.20) (0.91) (164.92) (0.10) (0.69) (18.45) (0.13) (1.16)
Observational Study
Model I, ρ = 0.2 9.11 0.76 6.70 773.35 0.49 4.24 50.38 0.182 7.11
(2.10) (0.14) (1.06) (164.86) (0.15) (0.81) (28.30) (0.09) (0.87)
Model I, ρ = 0.5 7.22 0.83 5.82 779.48 0.55 3.84 42.70 0.20 6.56
(1.54) (0.13) (0.86) (160.39) (0.14) (0.76) (24.25) (0.10) (0.74)
Model I, ρ = 0.8 6.21 0.80 4.91 784.01 0.29 1.76 40.94 0.18 6.02
(1.11) (0.13) (0.80) (157.62) (0.1) (0.61) (19.95) (0.09) (0.55)
Model II, ρ = 0.2 8.25 0.80 6.34 705.38 0.56 4.34 48.10 0.19 7.12
(2.18) (0.18) (1.18) (185.85) (0.16) (0.84) (26.87) (0.10) (0.91)
Model II, ρ = 0.5 6.57 0.89 5.66 743.78 0.60 3.81 43.33 0.20 6.58
(1.65) (0.14) (0.95) (175.07) (0.14) (0.79) (25.16) (0.10) (0.74)
Model II, ρ = 0.8 5.61 0.91 5.05 772.98 0.29 1.60 40.99 0.18 6.04
(0.79) (0.12) (0.77) (161.88) (0.1) (0.55) (19.20) (0.07) (0.56)
Model III, ρ = 0.2 10.95 0.64 6.55 746.16 0.43 4.33 49.26 0.19 7.21
(3.11) (0.18) (1.19) (175.46) (0.14) (0.86) (28.36) (0.09) (0.84)
Model III, ρ = 0.5 9.77 0.63 5.69 756.17 0.45 4.06 44.53 0.19 6.68
(3.08) (0.19) (1.06) (167.10) (0.15) (0.84) (25.24) (0.10) (0.81)
Model III, ρ = 0.8 7.22 0.70 4.79 770.29 0.29 2.06 41.58 0.18 6.15
(2.01) (0.18) (0.88) (161.25) (0.09) (0.78) (19.64) (0.08) (0.65)
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Table 4
Estimated optimal values and error rates of sequential advantage selection (SAS), S-score
and LASSO methods for the scenarios with the first choice of β (eight important
prescriptive variables: X1, X9, X10, X20, X22, X30, X35 and X40). True value Q(gopt) is
the mean response following the true optimal treatment regime gopt, while Q(gˆopt) is the
mean response following the estimated optimal treatment regime gˆopt of the three methods.
The mean response of each optimal treatment regime is obtained by the average outcome of
Monte Carlo simulation using the true model with 10,000 replicates. Err.rate stands for
error rate of the estimated optimal treatment regime, which is the proportion of individuals
with misspecified optimal treatment following the estimated optimal treatment regime. The
quantity in parenthesis is standard deviation of corresponding value.
Setting
True Value SAS S Score LASSO
Q(gopt) Q(gˆopt) Err.rate Q(gˆopt) Err.rate Q(gˆopt) Err.rate
Randomized Study
Model I, ρ = 0.2 2.94 2.86(0.09) 0.072 2.60(0.16) 0.168 2.58(0.14) 0.454
Model I, ρ = 0.5 2.94 2.87(0.06) 0.072 2.65(0.15) 0.156 2.64(0.12) 0.462
Model I, ρ = 0.8 2.90 2.86(0.04) 0.058 2.49(0.06) 0.205 2.64(0.10) 0.468
Model II, ρ = 0.2 3.35 3.25(0.07) 0.089 3.08(0.15) 0.150 3.04(0.12) 0.462
Model II, ρ = 0.5 3.25 3.18(0.04) 0.075 2.98(0.14) 0.151 2.98(0.12) 0.468
Model II, ρ = 0.8 3.05 3.01(0.03) 0.056 2.63(0.06) 0.207 2.80(0.10) 0.471
Model III, ρ = 0.2 3.93 3.75(0.15) 0.117 3.58(0.18) 0.169 3.56(0.14) 0.452
Model III, ρ = 0.5 3.88 3.73(0.11) 0.105 3.58(0.17) 0.155 3.54(0.14) 0.457
Model III, ρ = 0.8 3.60 3.52(0.08) 0.076 3.19(0.07) 0.201 3.30(0.11) 0.466
Observational Study
Model I, ρ = 0.2 2.94 2.89(0.04) 0.061 2.70(0.12) 0.137 2.77(0.06) 0.313
Model I, ρ = 0.5 2.94 2.88(0.03) 0.066 2.73(0.11) 0.132 2.82(0.05) 0.305
Model I, ρ = 0.8 2.90 2.86(0.02) 0.057 2.50(0.06) 0.202 2.81(0.05) 0.300
Model II, ρ = 0.2 3.35 3.26(0.07) 0.089 3.16(0.09) 0.129 3.22(0.06) 0.301
Model II, ρ = 0.5 3.25 3.18(0.04) 0.077 3.05(0.11) 0.131 3.13(0.05) 0.299
Model II, ρ = 0.8 3.05 3.01(0.02) 0.056 2.63(0.05) 0.206 2.95(0.05) 0.299
Model III, ρ = 0.2 3.93 3.79(0.10) 0.106 3.67(0.13) 0.144 3.77(0.07) 0.306
Model III, ρ = 0.5 3.88 3.73(0.09) 0.107 3.65(0.13) 0.137 3.74(0.06) 0.304
Model III, ρ = 0.8 3.60 3.53(0.04) 0.076 3.21(0.07) 0.195 3.48(0.05) 0.303
A
.
F
a
n
et
a
l./
S
A
S
fo
r
O
p
tim
a
l
T
rea
tm
en
t
R
egim
es
2
2
Fig 2. Solution path of sequential advantage selection (SAS), S-score and LASSO methods. These plots are from the randomized study with the
first choice of β (three important prescriptive variables: X1, X9 and X10), and are given for all combinations of three baseline functions and three
choices of correlations of covariates. Black solid line: SAS method; Red dashed line: S-score method; blue dot-dashed line: LASSO method.
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Fig 3. Solution path of sequential advantage selection (SAS), S-score and LASSO methods. These plots are from the randomized study with the
second choice of β (eight important prescriptive variables: X1, X9, X10, X20, X22, X30, X35 and X40), and are given for all combinations of three
baseline functions and three choices of correlations of covariates. Black solid line: SAS method; Red dashed line: S-score method; blue dot-dashed
line: LASSO method.
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Fig 4. Solution path of sequential advantage selection (SAS), S-score and LASSO methods. These plots are from the observational study with
the first choice of β (three important prescriptive variables: X1, X9 and X10), and are given for all combinations of three baseline functions and
three choices of correlations of covariates. Black solid line: SAS method; Red dashed line: S-score method; blue dot-dashed line: LASSO method.
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Fig 5. Solution path of sequential advantage selection (SAS), S-score and LASSO methods. These plots are from the observational study with the
second choice of β (eight important prescriptive variables: X1, X9, X10, X20, X22, X30, X35 and X40), and are given for all combinations of three
baseline functions and three choices of correlations of covariates. Black solid line: SAS method; Red dashed line: S-score method; blue dot-dashed
line: LASSO method.
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Table 5
List of covariates used in application of sequential advantage selection method on the
STAR*D study.
PARTICIPANT FEATURES
1 Gender 2-6 Ethnicity
7 Economic study consent 8 Depressed mood
9 Diminished interest or pleasure 10 Weight loss while not dieting
11 Insomnia or hypersomnia 12 Psychomotor agitation or retardation
13 Fatigue or loss of energy 14 Feelings of worthless or guilt
15 Diminished ability to concentrate 16 Recurrent thoughts of death or suicide
17 Age 18 Number of relatives living with patient
19 Number of friends living with patient 20 Total number of persons in household
21 Years of schooling completed 22 Highest degree received
23 On medical or psychiatric leave 24 Medicare
25 Medicaid 26 Private insurance
27 Better able make important decisions 28 Better able to enjoy things
29 Impact of your family and friends 30-35 Current marital status
36-41 Current employment status 42-44 Currently a student
45-46 Currently do volunteer work
ILLNESS FEATURES
47-60 Cumulative Illness Rating Scale 61-78 Hamilton rating scale for depression
79-93 Quick Inventory of Depressive Symptomatology 94-97 Medication history
98-236 Psychiatric diagnostic screening questionare 237 Baseline Axis I psychiatric condition
238 Baseline Axis II psychiatric condition 239 Family hx depression
240 Family hx bipolar disorder 241 Family hx alcohol abuse
242 Family hx drug abuse 243 Family hx suicide
INTERMEDIATE MEDICAL CONDITIONS
244-294 Patient rated inventory of side effects 295 AIDS-C percent improvement
296 QIDS-C score change rate 297 QIDS-SR score change rate
298 FISER frequency score change rate 299 FISER intensity score change rate
300 GRSEB score change rate 301 CGII score change rate
302 Patient presently a suicide risk 303 Patient in remission
304 Study medical daily dose
CARE FEATURES
305 Type of clinical site
